Free Trial

Oppenheimer Issues Pessimistic Forecast for Alumis (NASDAQ:ALMS) Stock Price

Alumis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Oppenheimer cut its price target on Alumis to $28 but maintained an “outperform” rating; that target implies about 427% upside from the stock’s current price.
  • Analyst sentiment is broadly positive: Alumis has a “Moderate Buy” consensus rating and a $31.27 average price target, though individual targets vary widely.
  • Shares opened at $5.32 after falling 5.1%. The company narrowly beat quarterly loss and revenue estimates, while reporting a net loss and remaining in clinical-stage drug development.
  • MarketBeat previews top five stocks to own in December.

Alumis (NASDAQ:ALMS - Get Free Report) had its price objective reduced by equities research analysts at Oppenheimer to $28.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Oppenheimer's target price suggests a potential upside of 426.71% from the company's current price.

ALMS has been the topic of a number of other research reports. Morgan Stanley reduced their price target on Alumis from $39.00 to $29.00 and set an "overweight" rating on the stock in a report on Wednesday, September 2nd. HC Wainwright dropped their price objective on Alumis from $15.00 to $9.00 and set a "buy" rating for the company in a report on Friday. Citigroup reiterated an "overweight" rating on shares of Alumis in a report on Tuesday, September 1st. Robert W. Baird set a $27.00 price objective on Alumis in a research report on Tuesday, September 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research note on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.27.

View Our Latest Analysis on ALMS

Alumis Stock Down 5.1%

Shares of Alumis stock opened at $5.32 on Monday. The company's fifty day simple moving average is $7.24 and its two-hundred day simple moving average is $20.46. Alumis has a 12-month low of $5.44 and a 12-month high of $31.35. The firm has a market cap of $688.08 million, a PE ratio of -1.50 and a beta of -0.28.

Alumis (NASDAQ:ALMS - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.03. The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.90 million. Alumis had a negative net margin of 5,844.54% and a negative return on equity of 89.77%. As a group, sell-side analysts expect that Alumis will post -2.95 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Srinivas Akkaraju purchased 546,581 shares of the firm's stock in a transaction that occurred on Tuesday, September 8th. The stock was bought at an average cost of $10.63 per share, with a total value of $5,810,156.03. Following the completion of the purchase, the director directly owned 4,937,026 shares in the company, valued at approximately $52,480,586.38. This represents a 12.45% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 99,754 shares of company stock worth $1,037,804 in the last 90 days. 33.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC bought a new position in Alumis in the second quarter worth $33,000. KBC Group NV purchased a new position in Alumis during the first quarter valued at $42,000. State of Wyoming bought a new stake in shares of Alumis during the 1st quarter valued at $57,000. Dimensional Fund Advisors LP boosted its holdings in shares of Alumis by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 23,115 shares of the company's stock valued at $509,000 after buying an additional 2,599 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of Alumis by 600.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company's stock worth $69,000 after buying an additional 2,684 shares during the period.

About Alumis

(Get Free Report)

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.

Recommended Stories

Analyst Recommendations for Alumis (NASDAQ:ALMS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alumis Right Now?

Before you consider Alumis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.

While Alumis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines